Strategies for the Management of Intraprocedural Thromboembolic Complications with Abciximab (ReoPro)

David Fiorella, Felipe C. Albuquerque, Patrick Han, Cameron McDougall, Ricardo A. Hanel, L. Nelson Hopkins, Joel D. MacDonald

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: Most complications related to endovascular neurointerventional procedures are thromboembolic. The objective of this study was to determine whether abciximab, a glycoprotein IIb/IIIa inhibitor, is a safe and effective agent for the treatment of thromboembolic complications encountered during interventional neuroradiological procedures. METHODS: A search of a prospectively maintained database identified 13 patients who were treated for intraprocedural thromboembolic complications with abciximab, either alone or in combination with tissue plasminogen activator, during a 22-month period. RESULTS: Of the 13 patients in our series (10 with aneurysms, 3 with arteriovenous malformations), 12 presented with unsecured vascular lesions, and in 9 cases the lesions were either acutely (<10 d) or subacutely (<6 mo) hemorrhagic. After the identification of a thromboembolic complication, each patient was treated with either intra-arterial (n = 5) or intravenous (n = 8) abciximab. Abciximab was administered intravenously as a 0.25-mg/kg bolus (n = 2), a 0.25-mg/kg bolus followed by a 12-hour 0.125-μg/kg/min infusion (n = 5), or a 12-hour 0.125-μg/kg/min infusion alone (n = 1). Intra-arterial abciximab (3.5-10 mg) was administered directly through a microcatheter positioned in the vicinity of the thrombus (n = 5). Five patients also were administered alteplase. Complete (n = 7) or partial (n = 6) resolution of thrombus was observed in all cases. Five patients had small infarcts in the distribution of the thromboembolic complication. In no case was new or increased hemorrhaging observed after thrombolysis. CONCLUSION: Abciximab (ReoPro), administered either intravenously or intra-arterially, is a viable option for the management of thromboembolic complications encountered during endovascular therapeutic procedures.

Original languageEnglish (US)
Pages (from-to)1089-1098
Number of pages10
JournalNeurosurgery
Volume54
Issue number5
DOIs
StatePublished - Jan 1 2004
Externally publishedYes

Fingerprint

Endovascular Procedures
Tissue Plasminogen Activator
Thrombosis
Platelet Glycoprotein GPIIb-IIIa Complex
Arteriovenous Malformations
abciximab
Aneurysm
Blood Vessels
Databases
Therapeutics

Keywords

  • Abciximab
  • Alteplase
  • Aneurysm
  • Arteriovenous malformation
  • Guglielmi detachable coils
  • Thrombolysis

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Fiorella, D., Albuquerque, F. C., Han, P., McDougall, C., Hanel, R. A., Hopkins, L. N., & MacDonald, J. D. (2004). Strategies for the Management of Intraprocedural Thromboembolic Complications with Abciximab (ReoPro). Neurosurgery, 54(5), 1089-1098. https://doi.org/10.1227/01.NEU.0000119351.86658.1D

Strategies for the Management of Intraprocedural Thromboembolic Complications with Abciximab (ReoPro). / Fiorella, David; Albuquerque, Felipe C.; Han, Patrick; McDougall, Cameron; Hanel, Ricardo A.; Hopkins, L. Nelson; MacDonald, Joel D.

In: Neurosurgery, Vol. 54, No. 5, 01.01.2004, p. 1089-1098.

Research output: Contribution to journalArticle

Fiorella, D, Albuquerque, FC, Han, P, McDougall, C, Hanel, RA, Hopkins, LN & MacDonald, JD 2004, 'Strategies for the Management of Intraprocedural Thromboembolic Complications with Abciximab (ReoPro)', Neurosurgery, vol. 54, no. 5, pp. 1089-1098. https://doi.org/10.1227/01.NEU.0000119351.86658.1D
Fiorella, David ; Albuquerque, Felipe C. ; Han, Patrick ; McDougall, Cameron ; Hanel, Ricardo A. ; Hopkins, L. Nelson ; MacDonald, Joel D. / Strategies for the Management of Intraprocedural Thromboembolic Complications with Abciximab (ReoPro). In: Neurosurgery. 2004 ; Vol. 54, No. 5. pp. 1089-1098.
@article{094b5fbce0774d91b8a6756734556243,
title = "Strategies for the Management of Intraprocedural Thromboembolic Complications with Abciximab (ReoPro)",
abstract = "OBJECTIVE: Most complications related to endovascular neurointerventional procedures are thromboembolic. The objective of this study was to determine whether abciximab, a glycoprotein IIb/IIIa inhibitor, is a safe and effective agent for the treatment of thromboembolic complications encountered during interventional neuroradiological procedures. METHODS: A search of a prospectively maintained database identified 13 patients who were treated for intraprocedural thromboembolic complications with abciximab, either alone or in combination with tissue plasminogen activator, during a 22-month period. RESULTS: Of the 13 patients in our series (10 with aneurysms, 3 with arteriovenous malformations), 12 presented with unsecured vascular lesions, and in 9 cases the lesions were either acutely (<10 d) or subacutely (<6 mo) hemorrhagic. After the identification of a thromboembolic complication, each patient was treated with either intra-arterial (n = 5) or intravenous (n = 8) abciximab. Abciximab was administered intravenously as a 0.25-mg/kg bolus (n = 2), a 0.25-mg/kg bolus followed by a 12-hour 0.125-μg/kg/min infusion (n = 5), or a 12-hour 0.125-μg/kg/min infusion alone (n = 1). Intra-arterial abciximab (3.5-10 mg) was administered directly through a microcatheter positioned in the vicinity of the thrombus (n = 5). Five patients also were administered alteplase. Complete (n = 7) or partial (n = 6) resolution of thrombus was observed in all cases. Five patients had small infarcts in the distribution of the thromboembolic complication. In no case was new or increased hemorrhaging observed after thrombolysis. CONCLUSION: Abciximab (ReoPro), administered either intravenously or intra-arterially, is a viable option for the management of thromboembolic complications encountered during endovascular therapeutic procedures.",
keywords = "Abciximab, Alteplase, Aneurysm, Arteriovenous malformation, Guglielmi detachable coils, Thrombolysis",
author = "David Fiorella and Albuquerque, {Felipe C.} and Patrick Han and Cameron McDougall and Hanel, {Ricardo A.} and Hopkins, {L. Nelson} and MacDonald, {Joel D.}",
year = "2004",
month = "1",
day = "1",
doi = "10.1227/01.NEU.0000119351.86658.1D",
language = "English (US)",
volume = "54",
pages = "1089--1098",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Strategies for the Management of Intraprocedural Thromboembolic Complications with Abciximab (ReoPro)

AU - Fiorella, David

AU - Albuquerque, Felipe C.

AU - Han, Patrick

AU - McDougall, Cameron

AU - Hanel, Ricardo A.

AU - Hopkins, L. Nelson

AU - MacDonald, Joel D.

PY - 2004/1/1

Y1 - 2004/1/1

N2 - OBJECTIVE: Most complications related to endovascular neurointerventional procedures are thromboembolic. The objective of this study was to determine whether abciximab, a glycoprotein IIb/IIIa inhibitor, is a safe and effective agent for the treatment of thromboembolic complications encountered during interventional neuroradiological procedures. METHODS: A search of a prospectively maintained database identified 13 patients who were treated for intraprocedural thromboembolic complications with abciximab, either alone or in combination with tissue plasminogen activator, during a 22-month period. RESULTS: Of the 13 patients in our series (10 with aneurysms, 3 with arteriovenous malformations), 12 presented with unsecured vascular lesions, and in 9 cases the lesions were either acutely (<10 d) or subacutely (<6 mo) hemorrhagic. After the identification of a thromboembolic complication, each patient was treated with either intra-arterial (n = 5) or intravenous (n = 8) abciximab. Abciximab was administered intravenously as a 0.25-mg/kg bolus (n = 2), a 0.25-mg/kg bolus followed by a 12-hour 0.125-μg/kg/min infusion (n = 5), or a 12-hour 0.125-μg/kg/min infusion alone (n = 1). Intra-arterial abciximab (3.5-10 mg) was administered directly through a microcatheter positioned in the vicinity of the thrombus (n = 5). Five patients also were administered alteplase. Complete (n = 7) or partial (n = 6) resolution of thrombus was observed in all cases. Five patients had small infarcts in the distribution of the thromboembolic complication. In no case was new or increased hemorrhaging observed after thrombolysis. CONCLUSION: Abciximab (ReoPro), administered either intravenously or intra-arterially, is a viable option for the management of thromboembolic complications encountered during endovascular therapeutic procedures.

AB - OBJECTIVE: Most complications related to endovascular neurointerventional procedures are thromboembolic. The objective of this study was to determine whether abciximab, a glycoprotein IIb/IIIa inhibitor, is a safe and effective agent for the treatment of thromboembolic complications encountered during interventional neuroradiological procedures. METHODS: A search of a prospectively maintained database identified 13 patients who were treated for intraprocedural thromboembolic complications with abciximab, either alone or in combination with tissue plasminogen activator, during a 22-month period. RESULTS: Of the 13 patients in our series (10 with aneurysms, 3 with arteriovenous malformations), 12 presented with unsecured vascular lesions, and in 9 cases the lesions were either acutely (<10 d) or subacutely (<6 mo) hemorrhagic. After the identification of a thromboembolic complication, each patient was treated with either intra-arterial (n = 5) or intravenous (n = 8) abciximab. Abciximab was administered intravenously as a 0.25-mg/kg bolus (n = 2), a 0.25-mg/kg bolus followed by a 12-hour 0.125-μg/kg/min infusion (n = 5), or a 12-hour 0.125-μg/kg/min infusion alone (n = 1). Intra-arterial abciximab (3.5-10 mg) was administered directly through a microcatheter positioned in the vicinity of the thrombus (n = 5). Five patients also were administered alteplase. Complete (n = 7) or partial (n = 6) resolution of thrombus was observed in all cases. Five patients had small infarcts in the distribution of the thromboembolic complication. In no case was new or increased hemorrhaging observed after thrombolysis. CONCLUSION: Abciximab (ReoPro), administered either intravenously or intra-arterially, is a viable option for the management of thromboembolic complications encountered during endovascular therapeutic procedures.

KW - Abciximab

KW - Alteplase

KW - Aneurysm

KW - Arteriovenous malformation

KW - Guglielmi detachable coils

KW - Thrombolysis

UR - http://www.scopus.com/inward/record.url?scp=2342513407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342513407&partnerID=8YFLogxK

U2 - 10.1227/01.NEU.0000119351.86658.1D

DO - 10.1227/01.NEU.0000119351.86658.1D

M3 - Article

C2 - 15113462

AN - SCOPUS:2342513407

VL - 54

SP - 1089

EP - 1098

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 5

ER -